1-3 of 3
Daniel Anderson
Close
Sort by
Journal Articles

Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML

Steffan T. Nawrocki, PhD, Yingchun Han, MD, Ronan LE Moigne, PhD, Valeria Visconte, PhD, Bartlomiej Przychodzen, MSc, Mark Rolfe, PhD, Stevan Djakovic, PhD, Daniel Anderson, David Wustrow, PhD, Han-Jie Zhou, Steve Wong, PhD, Anjali Advani, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS, Kevin R. Kelly, MD PhD, Jennifer S. Carew, PhD
Journal: Blood
Blood (2015) 126 (23): 1350.
https://doi.org/10.1182/blood.V126.23.1350.1350
Published: 2015
Journal Articles

Optimization of a BCR-ABL-Specific DNA Vaccine against Ph+ ALL Using a Nonviral Vector System and Nanoparticle Delivery

Yvonne Rott, Stefanie Arndt, Jordan Green, Daniel Anderson, Renata Stripecke, Burghardt Wittig, Manuel Schmidt, Joachim Köchling
Journal: Blood
Blood (2008) 112 (11): 4625.
https://doi.org/10.1182/blood.V112.11.4625.4625
Published: 2008
Journal Articles

Prevention of Ph + Acute Lymphoblastic Leukemia by Nanoparticulate Delivery of a DNA Vaccine in Syngeneic Mice.

Joachim Koechling, MD, Yvonne Rott, Stefanie Arndt, Jordan Green, Ph.D., Daniel Anderson, Ph.D., Robert Langer, Ph.D., Renata Stripecke, Ph.D., Burghardt Wittig, M.D. Ph. D, Manuel Schmidt
Journal: Blood
Blood (2007) 110 (11): 5135.
https://doi.org/10.1182/blood.V110.11.5135.5135
Published: 2007